Hydrogel-based biological delivery vehicle
A hydrogel-based biological delivery vehicle used to effectively deliver drug and biological material to tissue or organ sites. More specifically, a hydrogel binding matrix having a biopolymer backbone containing carboxyl groups. Tyramine may be substituted for at least a portion of the carboxyl groups, so that, when hydrogen peroxide is added, it causes creation of covalent bonds between tyramine molecules and cross-links the hydrogel binding matrix, thereby enabling the hydrogel binding matrix to transition from liquid to gel state. The hydrogel binding matrix, in its liquid form, is capable of encapsulating drug reservoirs to create a homogenous liquid with evenly distributed particles containing drugs or target molecules. As the hydrogel binding matrix solidifies into a gel state, the newly created cross-links do not disrupt or react with the drugs or target molecules contained within the drug reservoirs. This hydrogel-based biological delivery vehicle can be used in several medical applications.
1. A hydrogel-based drug delivery vehicle for delivering a drug to a wound comprising:
a) a first hydrogel matrix comprising a solvent and a plurality of chains of a first biopolymer dissolved in the solvent, the first biopolymer having a structure:
wherein n is an integer greater than or equal to 220;
wherein R is COOH or tyramine and wherein 1.5 mol % of R of the first biopolymer is tyramine;
wherein the first hydrogel matrix comprises from 1 mol % to 2 mol % of the first biopolymer and water as the solvent; and
wherein the solvent comprises water;
b) a plurality of drug reservoirs dispersed throughout the first hydrogel matrix; and
c) a cross-linking agent, wherein the cross-linking agent cross links tyramines within the first hydrogel matrix.
2. The hydrogel-based drug delivery vehicle of claim 1 , wherein the drug reservoirs comprise an analgesic.
3. The hydrogel-based drug delivery vehicle of claim 2 , wherein the analgesic is bupivacaine.
4. The hydrogel-based drug delivery vehicle of claim 1 , wherein each of the plurality of drug reservoirs comprise:
i) a second hydrogel matrix comprising a solvent and a plurality of chains of a second biopolymer comprising:
wherein n is an integer greater than or equal to 220;
wherein R 1 is COOH or tyramine and wherein more than 1.5 mol % of R1 of the second biopolymer is tyramine;
wherein a concentration of the second biopolymer in the second hydrogel matrix is greater than a concentration of the first biopolymer in the first hydrogel matrix and
wherein the solvent comprises water; and
ii) an analgesic agent dispersed within the each of the plurality of drug reservoirs.
5. The hydrogel-based drug delivery vehicle of claim 4 , wherein the analgesic is bupivacaine.
6. The hydrogel-based drug delivery vehicle of claim 1 , further comprising horseradish peroxidase and wherein the cross-linking agent is hydrogen peroxide.
7. The hydrogel-based drug delivery vehicle of claim 1 , wherein the osmolality of the first hydrogel matrix is higher than physiologic osmolality of the wound.
8. The hydrogel-based drug delivery vehicle of claim 7 , wherein the osmolality of the first hydrogel matrix is higher than 295 mOsm/Kg.
9. The hydrogel-based drug delivery vehicle of claim 7 , wherein the first hydrogel matrix swells upon implantation into the wound.
10. The hydrogel-based drug delivery vehicle of claim 9 , wherein the first hydrogel matrix absorbs fluid from surrounding tissue upon implantation into the wound.
11. The hydrogel-based drug delivery vehicle of claim 9 , wherein the first hydrogel matrix inhibits wound bleeding upon implantation into the wound.
12. The hydrogel-based drug delivery vehicle of claim 1 that is loaded in a syringe.
13. A hydrogel-based drug delivery vehicle for delivering a drug to a wound comprising:
a) a first hydrogel matrix comprising a solvent and a plurality of chains of a first biopolymer dissolved in the solvent, the first biopolymer having a structure:
wherein n is an integer greater than or equal to 220;
wherein R is COOH or tyramine and
wherein 1.5 mol % of R of the first biopolymer is tyramine; and wherein the first hydrogel matrix comprises from 0.5 mol % to 1.5 mol % of the first biopolymer and water as the solvent; and wherein the osmolality of the first hydrogel matrix is higher than 295 mOsm/Kg;
b) a plurality of drug reservoirs dispersed throughout the first hydrogel matrix, each of the plurality of drug reservoirs comprising:
i) a second hydrogel matrix comprising a solvent and a second biopolymer comprising:
wherein n is an integer greater than or equal to 220;
wherein R 1 is COOH or tyramine and
wherein more than 1.5 mol % of R1 of the second biopolymer is tyramine;
wherein a concentration of the second biopolymer in the second hydrogel matrix is greater than a concentration of the first biopolymer in the first hydrogel matrix and
wherein the solvent comprises water; and
ii) an analgesic agent dispersed within the each of the plurality of drug reservoirs; and
c) a cross-linking agent, wherein the cross-linking agent cross links tyramines within the first and second hydrogel matrix.
14. The hydrogel-based drug delivery vehicle of claim 13 , wherein first hydrogel matrix swells upon implementation into the wound.
15. The hydrogel-based drug delivery vehicle of claim 14 , wherein the first hydrogel matrix absorbs fluid from surrounding the cross-linking agent is hydrogen peroxide.
16. The hydrogel-based drug delivery vehicle of claim 14 , further comprising horseradish peroxide and wherein the cross-linking agent is hydrogen peroxide.